These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 10580431

  • 21. Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione.
    Kautzky-Willer A, Tura A, Winzer C, Wagner OF, Ludvik B, Hanusch-Enserer U, Prager R, Pacini G.
    Diabetes Obes Metab; 2006 Sep; 8(5):561-7. PubMed ID: 16918591
    [Abstract] [Full Text] [Related]

  • 22. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 23. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [Abstract] [Full Text] [Related]

  • 24. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S, Raskin P, Fonseca V, Graveline JF.
    N Engl J Med; 1998 Mar 26; 338(13):861-6. PubMed ID: 9516220
    [Abstract] [Full Text] [Related]

  • 25. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.
    Yatagai T, Nakamura T, Nagasaka S, Kusaka I, Ishikawa SE, Yoshitaka A, Ishibashi S.
    Diabetes Res Clin Pract; 2004 Jan 26; 63(1):19-26. PubMed ID: 14693409
    [Abstract] [Full Text] [Related]

  • 26. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC, Tsang LW, Sorensen JP, Cockram CS.
    Diabetes Care; 1995 Mar 26; 18(3):307-14. PubMed ID: 7555472
    [Abstract] [Full Text] [Related]

  • 27. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
    Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW.
    Diabetes Care; 1998 Sep 26; 21(9):1462-9. PubMed ID: 9727892
    [Abstract] [Full Text] [Related]

  • 28. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
    Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM.
    Diabetes Care; 1997 Feb 26; 20(2):188-93. PubMed ID: 9118772
    [Abstract] [Full Text] [Related]

  • 29. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
    Huang Z, Wan X, Liu J, Deng W, Chen A, Liu L, Liu J, Wei G, Li H, Fang D, Li Y.
    Diabetes Technol Ther; 2013 Oct 26; 15(10):859-69. PubMed ID: 23991629
    [Abstract] [Full Text] [Related]

  • 30. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.
    Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, Kim D, Mudaliar S, Henry RR.
    Metabolism; 2003 May 26; 52(5):540-6. PubMed ID: 12759881
    [Abstract] [Full Text] [Related]

  • 31. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
    Gavin LA, Barth J, Arnold D, Shaw R.
    Endocr Pract; 2000 May 26; 6(4):305-10. PubMed ID: 11242607
    [Abstract] [Full Text] [Related]

  • 32. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
    Khan MA, St Peter JV, Xue JL.
    Diabetes Care; 2002 Apr 26; 25(4):708-11. PubMed ID: 11919129
    [Abstract] [Full Text] [Related]

  • 33. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone.
    Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS.
    Am J Physiol; 1996 Oct 26; 271(4 Pt 1):E742-7. PubMed ID: 8897863
    [Abstract] [Full Text] [Related]

  • 34. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
    Fonseca V, Foyt HL, Shen K, Whitcomb R.
    Diabetes Care; 2000 Mar 26; 23(3):354-9. PubMed ID: 10868865
    [Abstract] [Full Text] [Related]

  • 35. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
    Blonde L, Sandberg MI, Guthrie RD.
    Diabetes Care; 1999 Jun 26; 22(6):1004-6. PubMed ID: 10372262
    [No Abstract] [Full Text] [Related]

  • 36. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN.
    Diabet Med; 2000 Jan 26; 17(1):40-7. PubMed ID: 10691158
    [Abstract] [Full Text] [Related]

  • 37. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL, Faulds D.
    Drugs; 1999 Mar 26; 57(3):409-38. PubMed ID: 10193691
    [Abstract] [Full Text] [Related]

  • 38. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
    Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR.
    Diabetes; 2003 Mar 26; 52(3):667-74. PubMed ID: 12606507
    [Abstract] [Full Text] [Related]

  • 39. Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
    Yokoyama I, Yonekura K, Moritan T, Tateno M, Momose T, Ohtomo K, Inoue Y, Nagai R.
    J Nucl Med; 2001 Jul 26; 42(7):1005-10. PubMed ID: 11438619
    [Abstract] [Full Text] [Related]

  • 40. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.
    Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H.
    Diabet Med; 1994 Jul 26; 11(7):685-91. PubMed ID: 7955995
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.